Summary : This diagram illustrates the traditional coagulation cascade, detailing the sequence of events and factors involved in blood clotting via the intrinsic, extrinsic, and common pathways. flowchart: # Pathways : • Intrinsic pathway (green box): Initiated by factor XII, proceeds through XI, IX, and VIII, with activation steps indicated by "a" (e.g., XIIa, XIa, IXa). • Extrinsic pathway (red box): Initiated by tissue damage, which activates tissue factor (TF) and factor VIIa. • Common pathway (blue box): Both intrinsic and extrinsic pathways converge at factor X, leading to the activation of prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a fibrin clot. # Nodes : • XII → XIIa (Intrinsic) • XI → XIa (Intrinsic) • IX → IXa (Intrinsic) • Ca²⁺, PT, V (Intrinsic, Common) • TF/VIIa (Extrinsic) • Tissue damage (Extrinsic) • X → Xa (Common) • Prothrombin → Thrombin (Common) • Fibrinogen → Fibrin (Common) • XIII (Common) • Fibrin clot (Common) # Connectors : • Arrows indicate the direction of activation or conversion between factors. • Intrinsic and extrinsic pathways both feed into the activation of factor X in the common pathway. • Ca²⁺ and PT, V are required cofactors at specific steps. # Layout : • Three main colored sections: green (intrinsic, top left), red (extrinsic, top right), blue (common, bottom). • Flow proceeds from top (initiation) to bottom (clot formation). • Arrows show sequential activation and convergence of pathways. # Analysis : • The diagram clearly separates the intrinsic and extrinsic initiation mechanisms, both converging on the common pathway at factor X. • The cascade is highly sequential, with each activated factor catalyzing the next step. • Calcium ions (Ca²⁺) and phospholipids (PT) are essential cofactors at multiple steps. • The final outcome is the formation of a stable fibrin clot, highlighting the coordinated nature of the coagulation process.

A comprehensive pathophysiology diagram illustrating the human coagulation cascade and the specific pharmacodynamic sites of action for various anticoagulants. The diagram is divided into three functional zones: the Intrinsic Pathway (blue), starting with Factor XII; the Extrinsic Pathway (red), initiated by Tissue Factor (TF) and Factor VII; and the Common Pathway (purple), where the pathways converge at Factor X. The cascade terminates in the conversion of Fibrinogen (I) to Fibrin (Ia), forming a fibrin clot. A secondary visual element depicts a platelet clot associated with the extrinsic pathway. Key clinical pharmacotherapeutic targets are marked with color-coded symbols: Warfarin inhibits Factors IX, VII, X, and II; Unfractionated Heparin (UHEP) + Antithrombin III (ATIII) inactivates Factors XIIa, XIa, IXa, Xa, and IIa; Low-Molecular-Weight Heparin (LMWHEP) and Fondaparinux target Factor Xa; Direct Factor Xa inhibitors act on Factor Xa; and Dabigatran acts as a direct thrombin inhibitor (Factor IIa). This schematic is designed for medical education regarding hemostasis and thromboprophylaxis.

This medical schematic illustrates the physiological processes of hemostasis and fibrinolysis. Part A depicts the Coagulation Cascade, divided into the Intrinsic, Extrinsic, and Common pathways. The Intrinsic pathway (purple) is triggered by internal damaged surfaces, activating Factor XII to XIIa, followed by XI and IX. The Extrinsic pathway (green) begins with endothelial tissue damage and Tissue Factor (TF), activating Factor VII to VIIa. Both pathways converge at the Common pathway (blue) starting with the activation of Factor X to Xa. This leads to the conversion of prothrombin (II) to thrombin (IIa), and fibrinogen (I) to fibrin (Ia), culminating in a stable fibrin clot stabilized by Factor XIIIa. Activated factors are denoted by an 'a' suffix. Part B illustrates Fibrinolysis, where tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators convert plasminogen to plasmin, which then degrades the fibrin network of the blood clot. Inhibitory regulators including PAI-1, PAI-2, and ̡2-antiplasmin are also shown. The diagram represents the structural breakdown of a clot containing platelets and red blood cells into fibrin degradation products.

Fourier-Transform Infrared (FTIR) spectroscopy comparison chart displaying the molecular finger-printing of octasulfate heparin (OSH), tristearin (solid lipid), Phosal® 53MCT (liquid lipid), and the resulting F10 nanostructured lipid carrier (NLC) formulation. The spectra are plotted across a wavenumber range of 4000 to 500 cm-1. OSH shows a distinctive broad O-H stretching band near 3300 cm-1 and sharp fingerprint peaks below 1500 cm-1. Tristearin exhibits intense, sharp doublets near 2900 cm-1 (C-H stretching) and a prominent carbonyl peak (C=O) near 1740 cm-1. Phosal® 53MCT demonstrates similar but broader lipid features. The F10 NLCs spectrum represents a composite formulation; it retains the characteristic broad O-H feature of OSH and the sharp aliphatic and carbonyl peaks of the lipid matrix (tristearin and Phosal®), confirming the successful incorporation of the drug into the lipid carrier without significant chemical alteration. This diagnostic chart is used in pharmaceutical science to evaluate drug-excipient compatibility and the integrity of nanoparticle formulations.

This diagnostic comparison chart displays Fourier-Transform Infrared (FTIR) spectra of biocompatible polymer matrices designed for tissue engineering and drug delivery. The image is divided into two panels: (A) xanthan-alginate (Xn-Alg) based materials and (B) xanthan-polyurethane (Xn-PU) based materials, both evaluated with and without chemical modification (XnOA) and heparin (Hep) loading. Key educational features include: - Broad absorption bands at approximately 3338–3373 cm⁻¹, signifying -OH and -NH- stretching vibrations essential for material hydration and structural stability. - Carbonyl group signals near 1737 cm⁻¹, used to verify the chemical modification of xanthan with oleic acid (XnOA). - Specific heparin markers, including sulphate group vibrations (S=O) at 1240–1249 cm⁻¹ and carboxylate (-COO-) stretching at 1433 cm⁻¹, which confirm successful incorporation of the anticoagulant into the scaffold. - Comparisons between matrices demonstrate the influence of polyurethane versus alginate on the hydrogen bonding and functional group distribution, critical for predicting material performance in human biomedical applications such as scaffold-based regeneration.

Summary : This diagram illustrates the traditional coagulation cascade, detailing the sequence of events and factors involved in blood clotting via the intrinsic, extrinsic, and common pathways. flowchart: # Pathways : • Intrinsic pathway (green box): Initiated by factor XII, proceeds through XI, IX, and VIII, with activation steps indicated by "a" (e.g., XIIa, XIa, IXa). • Extrinsic pathway (red box): Initiated by tissue damage, which activates tissue factor (TF) and factor VIIa. • Common pathway (blue box): Both intrinsic and extrinsic pathways converge at factor X, leading to the activation of prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a fibrin clot. # Nodes : • XII → XIIa (Intrinsic) • XI → XIa (Intrinsic) • IX → IXa (Intrinsic) • Ca²⁺, PT, V (Intrinsic, Common) • TF/VIIa (Extrinsic) • Tissue damage (Extrinsic) • X → Xa (Common) • Prothrombin → Thrombin (Common) • Fibrinogen → Fibrin (Common) • XIII (Common) • Fibrin clot (Common) # Connectors : • Arrows indicate the direction of activation or conversion between factors. • Intrinsic and extrinsic pathways both feed into the activation of factor X in the common pathway. • Ca²⁺ and PT, V are required cofactors at specific steps. # Layout : • Three main colored sections: green (intrinsic, top left), red (extrinsic, top right), blue (common, bottom). • Flow proceeds from top (initiation) to bottom (clot formation). • Arrows show sequential activation and convergence of pathways. # Analysis : • The diagram clearly separates the intrinsic and extrinsic initiation mechanisms, both converging on the common pathway at factor X. • The cascade is highly sequential, with each activated factor catalyzing the next step. • Calcium ions (Ca²⁺) and phospholipids (PT) are essential cofactors at multiple steps. • The final outcome is the formation of a stable fibrin clot, highlighting the coordinated nature of the coagulation process.

This medical schematic illustrates the physiological processes of hemostasis and fibrinolysis. Part A depicts the Coagulation Cascade, divided into the Intrinsic, Extrinsic, and Common pathways. The Intrinsic pathway (purple) is triggered by internal damaged surfaces, activating Factor XII to XIIa, followed by XI and IX. The Extrinsic pathway (green) begins with endothelial tissue damage and Tissue Factor (TF), activating Factor VII to VIIa. Both pathways converge at the Common pathway (blue) starting with the activation of Factor X to Xa. This leads to the conversion of prothrombin (II) to thrombin (IIa), and fibrinogen (I) to fibrin (Ia), culminating in a stable fibrin clot stabilized by Factor XIIIa. Activated factors are denoted by an 'a' suffix. Part B illustrates Fibrinolysis, where tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators convert plasminogen to plasmin, which then degrades the fibrin network of the blood clot. Inhibitory regulators including PAI-1, PAI-2, and ̡2-antiplasmin are also shown. The diagram represents the structural breakdown of a clot containing platelets and red blood cells into fibrin degradation products.

A comprehensive pathophysiology diagram illustrating the human coagulation cascade and the specific pharmacodynamic sites of action for various anticoagulants. The diagram is divided into three functional zones: the Intrinsic Pathway (blue), starting with Factor XII; the Extrinsic Pathway (red), initiated by Tissue Factor (TF) and Factor VII; and the Common Pathway (purple), where the pathways converge at Factor X. The cascade terminates in the conversion of Fibrinogen (I) to Fibrin (Ia), forming a fibrin clot. A secondary visual element depicts a platelet clot associated with the extrinsic pathway. Key clinical pharmacotherapeutic targets are marked with color-coded symbols: Warfarin inhibits Factors IX, VII, X, and II; Unfractionated Heparin (UHEP) + Antithrombin III (ATIII) inactivates Factors XIIa, XIa, IXa, Xa, and IIa; Low-Molecular-Weight Heparin (LMWHEP) and Fondaparinux target Factor Xa; Direct Factor Xa inhibitors act on Factor Xa; and Dabigatran acts as a direct thrombin inhibitor (Factor IIa). This schematic is designed for medical education regarding hemostasis and thromboprophylaxis.

TABLE 5 Half-Lives of Coagulation Factors <table><thead><tr><th>Factor</th><th>Half-Life Postinfusion (h)</th></tr></thead><tbody><tr><td>Fibrinogen</td><td>96–150</td></tr><tr><td>II</td><td>60</td></tr><tr><td>V</td><td>24</td></tr><tr><td>VII</td><td>4–6</td></tr><tr><td>VIII</td><td>11–12</td></tr><tr><td>IX</td><td>22</td></tr><tr><td>X</td><td>35</td></tr><tr><td>XI</td><td>60</td></tr><tr><td>XIII</td><td>144–300</td></tr><tr><td>VWF</td><td>8–12</td></tr></tbody></table> Republished with permission of McGraw Hill LLC, from Goodnight S, Hathaway W. Disorders of Hemostasis and Thrombosis: A Clinical Guide, second ed. New York, NY: McGraw-Hill Professional; 2001:497; permission conveyed through Copyright Clearance Center, Inc. VWF, von Willebrand factor.

TABLE 1: Rebalance of Hemostasis System Components in Cirrhosis <table><tr><th rowspan="2">Platelets</th><td>Thrombocytopenia</td><td rowspan="2">Coagulation</td><td>• Low levels of factors II, V, VII, IX, X, and XI<br>• Decreased platelet procoagulant surface<br>• Low levels of protein C and S and antithrombin; elevated factor VIII</td><td rowspan="2">Fibrinogen</td><td>• Low plasma levels<br>• Hypersialylation leading to decreased rates of fibrin polymerization<br>• Low FXIII<br>• Decreased permeability of the fibrin clot</td><td rowspan="2">Fibrinolysis</td><td>• Elevated tPA not balanced by elevated plasminogen activator inhibitor-1<br>• Low levels of α2-antiplasmin and TAFI<br>• Low plasminogen</td></tr><tr><td>Platelet (less platelet) malfunction when hematocrit is low</td><td>Normal to enhanced thrombin-generating capacity</td><td>Poorly studied</td><td>Controversial: decompensation appears to favor hyperfibrinolysis, but ACLF/sepsis can severely inhibit fibrinolysis</td></tr><tr><th>Changes promoting bleeding</th><td>Anemia</td><td>Changes promoting bleeding</td><td>• Low levels of factors II, V, VII, IX, X, and XI<br>• Decreased platelet procoagulant surface<br>• Low levels of protein C and S and antithrombin; elevated factor VIII</td><td>Changes promoting bleeding</td><td>• Low plasma levels<br>• Hypersialylation leading to decreased rates of fibrin polymerization<br>• Low FXIII<br>• Decreased permeability of the fibrin clot</td><td>Changes promoting bleeding</td><td>• Elevated tPA not balanced by elevated plasminogen activator inhibitor-1<br>• Low levels of α2-antiplasmin and TAFI<br>• Low plasminogen</td></tr><tr><th>Changes promoting clotting</th><td>Elevated levels of VWF<br>Decreased levels of ADAMTS13<br>Enhanced in vivo platelet activation<br>Activated endothelium</td><td>Changes promoting clotting</td><td>Low levels of protein C and S and antithrombin; elevated factor VIII</td><td>Changes promoting clotting</td><td>Poorly studied</td><td>Changes promoting clotting</td><td>Controversial: decompensation appears to favor hyperfibrinolysis, but ACLF/sepsis can severely inhibit fibrinolysis</td></tr><tr><th>Net effect</th><td>Poorly studied; elevated VWF compensates at least partly for thrombocytopenia</td><td>Net effect</td><td>Normal to enhanced thrombin-generating capacity</td><td>Net effect</td><td>Poorly studied</td><td>Net effect</td><td>Controversial: decompensation appears to favor hyperfibrinolysis, but ACLF/sepsis can severely inhibit fibrinolysis</td></tr></table>

TABLE VII.—Classification of topical hemostatic agents. <table><thead><tr><th>Category</th><th>Class</th><th>Origin</th><th>Mechanism(s) of action</th><th>Clinical features</th></tr></thead><tbody><tr><td>Topical absorbable hemostats</td><td>• Cellulose<br>• Gelatin<br>• Collagen<br>• Polysaccharide spheres</td><td>• Plant-derived<br>• Animals (bovine, swine, equine)</td><td>• Provide a clotting matrix<br>• Promote platelet activation and aggregation</td><td>• Indication for patients with no coagulative disorders<br>• Less effective in patients under antiplatelet therapy</td></tr><tr><td>Biological hemostatic agents</td><td>• Fibrin<br>• Thrombin<br>• Glutaraldehyde cross-linked albumin</td><td>• Human<br>• Plant-derived<br>• Animals (bovine, swine, equine)<br>• Bovine/synthetic</td><td>• Trigger the coagulation cascade<br>• Promote the clot formation<br>• Provide a chemical reaction between albumin and extracellular matrix</td><td>• Indication for patients with coagulative disorders<br>• More effective in vascular anastomosis<br>• Less effective in visceral and urological surgery</td></tr><tr><td>Mechanical barriers</td><td>• Inert mineral powder</td><td>• Mineral</td><td>• Formation of a mechanical barrier with the union of the mineral powder with water</td><td>• Indication for nonvariceal gastrointestinal bleeding</td></tr><tr><td>Surgical sealants</td><td>• Gelatin<br>• Glutaraldehyde<br>• Cyanoacrylate<br>• Polyethylene glycol esters<br>• Alcoholic solution of zein (corn protein)</td><td>• Human<br>• Human/synthetic<br>• Plant-derived<br>• Animals (swine)</td><td>• Solid film polymerization to connect tissue surfaces<br>• Formation of a hydrogel matrix</td><td>• Indication for tissue laceration or vascular graft bleeding</td></tr></tbody></table>

A comparison chart and pathophysiology diagram illustrating the local and systemic pharmacokinetic profiles of immediate-release versus controlled-release inhalation formulations. The top row features line graphs of pulmonary drug concentration over time. The immediate-release graph shows a sharp, high peak (Cmax) at tmax = t0, significantly exceeding the local toxicity threshold. The controlled-release graph depicts two profiles: a high initial encapsulated drug fraction and a lower, sustained active drug fraction that remains below the local toxicity limit. The middle section shows the mechanism of action: immediate-release involves rapid solubilizing drug particles penetrating lung fluids and parenchyma, while controlled-release shows nanocarriers releasing active drug fractions and interacting with alveolar macrophages. The bottom row presents plasmatic concentration graphs; the immediate-release formulation exhibits a rapid systemic Cmax correlated with higher systemic toxicities, whereas the controlled-release formulation demonstrates a blunted, delayed peak, indicating improved systemic safety. This educational graphic is intended for pharmacology and oncology instruction regarding inhaled drug delivery systems.

This composite educational graphic illustrates the role of Ferroptosis Suppressor Protein 1 (FSP1) as a warfarin-resistant vitamin K (VK) reductase. Panel (a) shows genomic schematic maps of Fsp1 wild-type and knockout alleles alongside genotyping PCR results. Panel (b) provides an immunoblot for FSP1 expression in adipose tissue, liver, and kidney across genotypes. Panel (c) displays gross morphological and H&E stained liver histology of Fsp1 mice, demonstrating normal architecture. Panel (d) outlines a clinical study design evaluating MK4 (vitamin K2) levels and prothrombin time under high-dose warfarin treatment. Panel (e) uses scatter plots to show the concentrations of MK4 and MK4 epoxide in liver and plasma. Panel (f) presents a clinical photograph comparing mouse brains: the warfarin-only specimen exhibits massive cerebral hemorrhage (dark discoloration), while the warfarin plus MK4 specimen appears normal, illustrating the antidotal effect of MK4. Finally, panel (g) provides pathophysiology flowcharts of the vitamin K cycle, detailing the enzymatic pathways involving VKOR and FSP1, and the mechanism by which high-dose vitamin K bypasses warfarin inhibition to enable carboxylation of coagulation factors.

A multi-panel pathophysiology diagram illustrating the mechanism of action of oral anticoagulants on the coagulation cascade. The top panel shows a linear pathway: the liver produces functional clotting factors, which undergo coagulation to become activated clotting factors (Xa and IIa/thrombin), ultimately leading to fibrin formation. Vitamin K antagonists (VKA) are shown inhibiting the liver's production of functional factors, while non-vitamin K antagonist oral anticoagulants (NOACs) inhibit the activated factors. The bottom-left panel details the biochemical mechanism of VKAs, showing they inhibit the glutamyl carboxylase and vitamin K-dependent conversion of glutamyl residues on protein precursors into carboxy-glutamyl residues on completed clotting proteins. The bottom-right panel provides a molecular-level view of NOAC action, depicting thrombin (orange sphere) and factor Xa (yellow head with blue tail) being inhibited at their respective active sites (indicated by grey coloring). This educational graphic highlights the distinction between indirect synthesis inhibition by VKAs and direct enzymatic inhibition by NOACs/DOACs.

This composite educational image, categorized as Clinical Imaging/Specimen, illustrates the role of blood coagulation Factor X in adenovirus transduction using a mouse model. Panel A presents two gross liver specimens stained for β-galactosidase activity (Lac-Z reporter gene). The specimen labeled 'Adenovirus + Warfarin' appears pale pink/tan, indicating minimal viral transduction due to warfarin-induced depletion of vitamin K-dependent factors. In contrast, the 'Adenovirus + Warfarin + Factor X' specimen shows intense dark blue-green staining across the hepatic surface, demonstrating that exogenous Factor X supplementation restores adenoviral infection. Panel B contains a corresponding bar graph quantifying the percentage of RNA expression in adrenal glands. The 'Adenovirus + Warfarin' group (black bar) shows significantly lower expression compared to the 'Adenovirus + Warfarin + Factor X' group (gray bar), which is set as the 100% reference point. Statistical significance is indicated by a p-value < 0.0001. This figure demonstrates that adenovirus type 5 infection in both liver and adrenal tissues is dependent on Factor X, bypassing traditional CAR receptor-mediated pathways.